Intensity Therapeutics Inc
Company Profile
Business description
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Contact
1 Enterprise Drive
Suite 430
SheltonCT06484-4779
USAT: +1 203 221-7381
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
stocks
Chart of the Week: The long term headwinds facing copper shares
stocks
Australia’s oldest REIT undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,930.90 | 9.20 | 0.10% |
| CAC 40 | 8,390.27 | 52.98 | 0.64% |
| DAX 40 | 25,123.29 | 83.01 | 0.33% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,525.96 | 47.62 | 0.45% |
| HKSE | 23,055.03 | 174.01 | 0.76% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 68,733.15 | 1,741.81 | -2.47% |
| NZX 50 Index | 13,582.19 | 28.31 | -0.21% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,724.50 | 13.90 | 0.16% |
| SSE Composite Index | 4,028.90 | 83.54 | -2.03% |